Aptose obtains CEO cash advance; warns of possible insolvency without additional funding in coming days

Aptose Biosciences Inc.

CEO William Rice provides non-interest bearing, unsecured short-term cash advance to support payroll and obligations.
Company warns it may not have sufficient resources and could enter insolvency proceedings without additional funding in coming days.
Director Carol Ashe resigned effective June 16, 2025.
Advance is a related-party transaction exempt from formal valuation and minority approval under MI 61-101.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.